| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $45,827,214 | 37 | 100 |
| SUPRAN BRYAN | EVP, CLO and Secretary | 0 | $0 | 1 | $398,855 | $-398,855 |
| PYOTT DAVID E I | director | 0 | $0 | 1 | $1.15M | $-1.15M |
| McLaughlin Melissa | Chief Human Resources Officer | 0 | $0 | 2 | $1.27M | $-1.27M |
| Tanguler Tolga | EVP, Chief Commercial Officer | 0 | $0 | 4 | $2.42M | $-2.42M |
| Poulton Jeffrey V. | EVP, Chief Financial Officer | 0 | $0 | 5 | $4.2M | $-4.2M |
| Garg Pushkal | EVP Chief R&D | 0 | $0 | 9 | $6.33M | $-6.33M |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | 0 | $0 | 9 | $9.63M | $-9.63M |
| Greenstreet Yvonne | Chief Executive Officer | 0 | $0 | 6 | $20.42M | $-20.42M |
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) …
Over the last 12 months, insiders at Alnylam Pharmaceuticals, Inc. have bought $0 and sold $45.83M worth of Alnylam Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Alnylam Pharmaceuticals, Inc. have bought $10,363 and sold $50.38M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 4 shares for transaction amount of $1,211 was made by Reitan Colleen F (director) on 2024‑10‑17.
| 2026-10-02 | Sale | SUPRAN BRYAN | EVP, CLO and Secretary | 1,758 0.0014% | $226.88 | $398,855 | +2.32% | |
| 2026-06-01 | Sale | PYOTT DAVID E I | director | 3,830 0.0029% | $299.18 | $1.15M | -16.58% | |
| 2026-04-06 | Sale | McLaughlin Melissa | Chief Human Resources Officer | 2,286 0.0017% | $330.42 | $755,329 | -17.46% | |
| 2026-04-02 | Sale | McLaughlin Melissa | Chief Human Resources Officer | 1,624 0.0012% | $319.59 | $519,014 | -13.63% | |
| 2026-03-05 | Sale | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | 658 0.0005% | $323.98 | $213,177 | -10.71% | |
| 2026-03-05 | Sale | Garg Pushkal | EVP Chief R&D | 2,404 0.0018% | $323.96 | $778,812 | -10.71% | |
| 2026-03-04 | Sale | Greenstreet Yvonne | Chief Executive Officer | 2,933 0.0022% | $323.08 | $947,581 | -12.54% | |
| 2026-03-04 | Sale | Poulton Jeffrey V. | EVP, Chief Financial Officer | 2,468 0.0018% | $323.08 | $797,351 | -12.54% | |
| 2026-03-04 | Sale | Tanguler Tolga | EVP, Chief Commercial Officer | 2,309 0.0017% | $323.08 | $745,984 | -12.54% | |
| 2026-03-04 | Sale | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | 633 0.0005% | $323.08 | $204,508 | -12.54% | |
| 2026-03-04 | Sale | Garg Pushkal | EVP Chief R&D | 2,309 0.0017% | $323.08 | $745,984 | -12.54% | |
| 2026-03-03 | Sale | Garg Pushkal | EVP Chief R&D | 1,775 0.0013% | $319.74 | $567,546 | -10.14% | |
| 2026-03-03 | Sale | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | 1,652 0.0012% | $319.73 | $528,189 | -10.14% | |
| 2026-03-02 | Sale | Greenstreet Yvonne | Chief Executive Officer | 6,799 0.005% | $327.65 | $2.23M | -11.89% | |
| 2026-03-02 | Sale | Poulton Jeffrey V. | EVP, Chief Financial Officer | 2,206 0.0016% | $327.65 | $722,801 | -11.89% | |
| 2026-03-02 | Sale | Tanguler Tolga | EVP, Chief Commercial Officer | 1,598 0.0012% | $327.65 | $523,584 | -11.89% | |
| 2026-03-02 | Sale | Garg Pushkal | EVP Chief R&D | 1,717 0.0013% | $327.66 | $562,585 | -11.89% | |
| 2026-03-02 | Sale | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | 1,598 0.0012% | $327.65 | $523,584 | -11.89% | |
| 2026-02-27 | Sale | Garg Pushkal | EVP Chief R&D | 4,627 0.0035% | $331.34 | $1.53M | -13.94% | |
| 2026-02-17 | Sale | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | 2,041 0.0015% | $331.96 | $677,532 | -13.38% |
| PYOTT DAVID E I | director | 1582 0.0012% | $252,945.98 | 1 | 3 | +45.98% |
| Sanofi | 10 percent owner | 10554134 7.8799% | $1.69B | 6 | 0 | +18.68% |
| NOVARTIS AG | 10 percent owner | 4051002 3.0245% | $647.71M | 3 | 1 | <0.0001% |
| Westphal Christoph H | director, 10 percent owner | 300170 0.2241% | $47.99M | 1 | 0 | +16.38% |
| CHP II LP | 10 percent owner | 232500 0.1736% | $37.17M | 1 | 0 | +16.38% |
| MARAGANORE JOHN | Chief Executive Officer | 214765 0.1603% | $34.34M | 9 | 42 | +49.04% |
| Abingworth Management LTD | 10 percent owner | 155367 0.116% | $24.84M | 2 | 6 | +44.17% |
| Berriman John E | director | 155367 0.116% | $24.84M | 1 | 0 | +16.38% |
| Greene Barry E | President | 70343 0.0525% | $11.25M | 7 | 18 | +53.61% |
| BONNEY MICHAEL W | director | 16804 0.0125% | $2.69M | 2 | 4 | <0.0001% |
| CLARKE JOHN K | director | 8891 0.0066% | $1.42M | 1 | 2 | |
| ATLAS VENTURE FUND V LP | 10 percent owner | 6557 0.0049% | $1.05M | 2 | 2 | +8.19% |
| KEATING LAURIE | EVP, Chief Legal Officer | 5132 0.0038% | $820,555.48 | 1 | 17 | +78.8% |
| Reid Laurence | SVP, Chief Business Officer | 3905 0.0029% | $624,370.45 | 1 | 7 | +41.4% |
| Barrett Peter | director | 2647 0.002% | $423,228.83 | 2 | 9 | +8.19% |
| PAUL STEVEN M | 2526 0.0019% | $403,882.14 | 1 | 3 | +10.44% | |
| Gros David-Alexandre C | SVP, Chief Business Officer | 1000 0.0007% | $159,890.00 | 1 | 0 | <0.0001% |
| Reitan Colleen F | director | 775 0.0006% | $123,914.75 | 2 | 3 | <0.0001% |
| SHARP PHILLIP A | director | 0 0% | $0 | 2 | 15 | +68.46% |
| SCHIMMEL PAUL | director | 0 0% | $0 | 2 | 15 | +27.77% |
| Fanucci Marsha | director | 0 0% | $0 | 1 | 2 | +41.4% |
$961,890,236 | 276 | 22.46% | $23.97B | |
$2,765,836 | 72 | 20.00% | $10.77B | |
$108,876,545 | 67 | 72.81% | $14.6B | |
$2,449,191,716 | 58 | 16.50% | $100.2B | |
$11,991,408 | 51 | 18.36% | $22.91B |
| Increased Positions | 469 | +50.43% | 9M | +7.11% |
| Decreased Positions | 413 | -44.41% | 11M | -8.53% |
| New Positions | 175 | New | 2M | New |
| Sold Out Positions | 116 | Sold Out | 3M | Sold Out |
| Total Postitions | 986 | +6.02% | 130M | -1.42% |
| Fmr Llc | $6.71M | 12.7% | 16.77M | +961,104 | +6.08% | 2025-09-30 |
| Capital World Investors | $6.58M | 12.45% | 16.43M | -370,754 | -2.21% | 2025-09-30 |
| Vanguard Group Inc | $5.43M | 10.28% | 13.57M | +268,313 | +2.02% | 2025-09-30 |
| Blackrock, Inc. | $3.96M | 7.5% | 9.9M | -76,562 | -0.77% | 2025-09-30 |
| Capital Research Global Investors | $2.89M | 5.47% | 7.22M | +31,184 | +0.43% | 2025-09-30 |
| Jpmorgan Chase & Co | $1.82M | 3.44% | 4.54M | +2M | +120.36% | 2025-09-30 |
| State Street Corp | $1.23M | 2.33% | 3.08M | -91,630 | -2.89% | 2025-09-30 |
| Baillie Gifford & Co | $1.12M | 2.11% | 2.79M | -242,535 | -8% | 2025-09-30 |
| Geode Capital Management, Llc | $1M | 1.89% | 2.5M | +100,472 | +4.19% | 2025-09-30 |
| Dodge & Cox | $928,887.00 | 1.76% | 2.32M | -875,866 | -27.4% | 2025-09-30 |